T-Cell Lymphomas: Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

In the 8MM, the diagnosed incident cases of TCL are expected to increase from 27,263 cases in 2020 growing at an Annual Growth Rate (AGR) of more than 2% during 2021-2030. There is an increase forecasted in the five-year diagnosed prevalent cases of TCL from 90,275 cases in 2020 at an AGR of more than 2.5%. In 2020, for the 8MM combined, adults ages 60-69 years contributed the highest proportion of the diagnosed incident cases of TCL with more than 20%, followed by the age group 70-79 years, and ages 50-59 years. In 2020, the number of diagnosed incident cases of TCL was higher in men than in women in the 8MM combined.

TCL is broadly separated into cutaneous TCL (CTCL) and peripheral TCL (PTCL). CTCL are cancers of the skin and account for 5% of all lymphomas (American Cancer Society, 2020). PTCL is a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. PTCL could be nodal such as in the lymph nodes and spleen, or extranodal such as in the gastrointestinal tract and nasal cavity. Anaplastic large-cell lymphoma (ALCL) is a major subtype that can occur in both CTCL and PTCL. This report provides an overview of the risk factors and the global and historical epidemiological trends for TCL in the eight major markets (8MM: The US, France, Germany, Italy, Spain, the UK, Japan, and urban China).

What are the diagnosed incident cases of TCL by CD30 Expression?

In 2020, more than 20% of diagnosed incident cases of CTCL had CD30 expression and more than 60% of PTCL cases had CD30 expression in the 8MM. Proportions were identical across all markets since a proportion from the US was used as a proxy.

Diagnosed incident cases of TCL by CD30 Expression

Diagnosed incident cases of TCL by CD30 Expression

For more segment insights, download a free report sample

What are the diagnosed incident cases of TCL by stage at diagnosis?

In the 8MM combined, the distribution shows that the majority of diagnosed incident cases of MF and SS were in stage IA, and the fewest were in stage IIIB in 2020. Italy and Spain had the highest proportion of MF and SS cases more than 50% diagnosed at stage IA, and the fewest cases diagnosed at stages IIIA and IVB. In France and Germany, most cases of MF and SS were diagnosed at stage IA, but the proportion of cases at stage IA (more than 25%) was the lowest when compared to the other 8MM. In the UK, the fewest number of cases were diagnosed at stage IVB.

What are the diagnosed incident cases of TCL in the 8MM?

In 2020, the US accounted for more than 20% of the diagnosed incident cases of TCL in the 8MM. There were more than 4,800 cases of TCL in the 5EU combined, making up more than 15%% of the cases in the 8MM in 2020. In 2020, Japan had diagnosed incident cases, accounting for more than 7% of the cases in the 8MM. In the 8MM, the number of diagnosed incident cases of TCL will grow at an Annual Growth Rate (AGR) of more than 2%, from 2020 to 2030. Of the 8MM, urban China is expected to see the largest growth, growing from 2020 to 2030 at an AGR of more than 4%. Japan is expected to see a decrease in cases, at a negative AGR of more than 0.5%. The increase in the diagnosed incident cases of TCL is attributed to the underlying demographic changes in the respective markets.

Diagnosed incident cases of TCL in the 8MM

Diagnosed incident cases of TCL in the 8MM

For more regional insights, download a free report sample

Market report scope

Key stages Stage I, Stage II, Stage III, and Stage IV
CD30 Expression CTCL and PTCL
Key Countries The US, France, Germany, Italy, Spain, the UK, Japan, and Urban China

Scope

This report provides an in-depth analysis of the following:

  • T-cell lymphomas (TCL) Epidemiology Report and Model provide an overview of the risk factors and global trends of TCL in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Urban China). For this report, TCL are broadly separated into cutaneous TCL (CTCL) and peripheral TCL (PTCL).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in all ages across the 8MM: diagnosed incident cases of TCL (CTCL and PTCL) segmented by sex and age (0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and 80 years and older); diagnosed five-year prevalent cases TCL; diagnosed incident cases of TCL (CTCL and PTCL) by cancer staging; and diagnosed incident cases of TCL with CD30 biomarker expression.
  • The TCL Epidemiology Report and Model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The TCL Epidemiology series will allow you to:

  • Develop business strategies by understanding the trends shaping and driving the global TCL market.
  • Quantify patient populations in the global TCL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the TCL cancer stages that present the best opportunities for TCL therapeutics in each of the markets covered.
  • Understand the magnitude of the TCL market by biomarker.

Table of Contents

| About GlobalData

1 T-Cell Lymphomas: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.5 Epidemiological Forecast for TCL (2020–2030)

2.5.1 Diagnosed Incident Cases of TCL

2.5.2 Age-Specific Diagnosed Incident Cases of TCL

2.5.3 Sex-Specific Diagnosed Incident Cases of TCL

2.5.4 Diagnosed Incident Cases of TCL by Subtype

2.5.5 Diagnosed Incident Cases of TCL by Stage at Diagnosis

2.5.6 Diagnosed Incident Cases of TCL by CD30 Expression

2.5.7 Five-Year Diagnosed Prevalent Cases of TCL

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Risk Factors and Comorbidities for TCL

Figures

Figure 1: 8MM, Diagnosed Incident Cases of TCL, Both Sexes, N, All Ages, 2020 and 2030

Figure 2: 8MM, Diagnosed Incidence of TCL, Men and Women, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 3: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL

Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of TCL by Subtype

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL By Stage at Diagnosis

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL by CD30 Expression

Figure 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of TCL

Figure 8: 8MM, Diagnosed Incident Cases of TCL, N, Both Sexes, All Ages, 2020

Figure 9: 8MM, Diagnosed Incident Cases of TCL by Age, N, Both Sexes, 2020

Figure 10: 8MM, Diagnosed Incident Cases of TCL by Sex, N, All Ages, 2020

Figure 11: 8MM, Diagnosed Incident Cases Proportion of TCL (CTCL and PTCL) by Subtype, %, Both Sexes, All Ages, 2020

Figure 12: 8MM, Diagnosed Incident Cases Proportions of MF and SS by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 13: 8MM, Diagnosed Incident Cases Proportion of Primary Cutaneous ALCL and Others by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 14: 8MM, Diagnosed Incident Cases Proportion of PTCL by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases Proportion of TCL with CD30 Expression, %, Both Sexes, All Ages, 2020

Figure 16: 8MM, Five-Year Diagnosed Prevalent Cases of TCL, N, Both Sexes, All Ages, 2020

Frequently asked questions

T-Cell Lymphomas: Epidemiology Forecast to 2030 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

T-Cell Lymphomas: Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at T-Cell Lymphomas: Epidemiology Forecast to 2030 in real time.

  • Access a live T-Cell Lymphomas: Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.